"The industry feels let down. We feel we were not given a fair chance. The government's order to ban 344 FDCs enblock is arbitrary and unfair," Indian drug manufacturers' association (IDMA) President S V Veerramani told reporters.
The products worth Rs 5,000 crore have been banned for manufacture, distribution and sale with immediate effect causing hardship to manufacturers and patients, he added.
In a gazette notification on March 10, the government had banned 344 FDCs including ban on manufacture, sale and distribution of fixed does combination of chlopheniramine maleate plus codiene syrup which is used in the cough syrups.
This is also not in the public interest as the patients will be denied useful FDCs, he added.
"The amount of time, money and environmental impact in destroying these procedures will be huge," Federation of Pharma Entrepreneurs (FOPE) Chairman R C Juneja said.
There was no proper discussion with the industry before the ban, he added.
Several companies have approached Delhi High Court, which has granted interim stay on the government decision.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
